Breaking Down InMode Ltd. (INMD) Financial Health: Key Insights for Investors

Breaking Down InMode Ltd. (INMD) Financial Health: Key Insights for Investors

IL | Healthcare | Medical - Devices | NASDAQ

InMode Ltd. (INMD) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding InMode Ltd. (INMD) Revenue Streams

Revenue Analysis

InMode Ltd. reported $420.4 million in total revenue for the fiscal year 2023, representing a 12.6% year-over-year growth from 2022.

Revenue Source 2023 Amount Percentage of Total Revenue
Aesthetic Surgical Platforms $312.5 million 74.3%
Aesthetic Non-Surgical Platforms $87.6 million 20.8%
Other Revenue Streams $20.3 million 4.9%

Regional revenue breakdown for 2023:

  • United States: $268.3 million (63.8% of total revenue)
  • Europe: $82.1 million (19.5% of total revenue)
  • Rest of World: $70 million (16.7% of total revenue)

Key revenue growth metrics for 2023:

  • Aesthetic Surgical Platforms revenue growth: 15.2%
  • Aesthetic Non-Surgical Platforms revenue growth: 9.7%
  • Gross margin: 81.4%



A Deep Dive into InMode Ltd. (INMD) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's operational effectiveness and revenue generation capabilities.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin 87.3% 86.9%
Operating Profit Margin 36.2% 34.7%
Net Profit Margin 29.5% 27.8%

Key profitability indicators demonstrate consistent financial performance across critical metrics.

  • Gross Profit: $326.4 million in 2023
  • Operating Income: $184.6 million in 2023
  • Net Income: $147.3 million in 2023
Efficiency Metrics 2023 Performance
Return on Equity (ROE) 23.6%
Return on Assets (ROA) 18.9%

Comparative industry analysis indicates strong competitive positioning with above-average profitability ratios.




Debt vs. Equity: How InMode Ltd. (INMD) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, InMode Ltd. demonstrates a strategic approach to capital structure with the following key financial metrics:

Debt Metric Value
Total Long-Term Debt $0
Short-Term Debt $0
Total Debt $0
Debt-to-Equity Ratio 0.00

The company's capital financing strategy is characterized by the following attributes:

  • No outstanding long-term or short-term debt
  • Primarily equity-funded growth model
  • Strong cash position from equity financing
Equity Financing Details Amount
Total Shareholders' Equity $491.84 million
Paid-in Capital $377.54 million

Financing characteristics include:

  • Zero reliance on external debt financing
  • Robust equity capital structure
  • Strong financial flexibility



Assessing InMode Ltd. (INMD) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Current and Quick Ratios

Liquidity Metric Value Year
Current Ratio 3.42 2023
Quick Ratio 2.89 2023

Working Capital Assessment

The company's working capital position demonstrates robust financial flexibility:

  • Total Working Capital: $124.6 million
  • Year-over-Year Working Capital Growth: 17.3%
  • Net Working Capital Ratio: 2.1x

Cash Flow Statement Overview

Cash Flow Category Amount Year
Operating Cash Flow $89.4 million 2023
Investing Cash Flow -$22.7 million 2023
Financing Cash Flow -$41.2 million 2023

Liquidity Strengths

  • Cash and Cash Equivalents: $215.3 million
  • Short-Term Investments: $67.9 million
  • Total Liquid Assets: $283.2 million

Debt and Solvency Indicators

Debt Metric Value Year
Total Debt $45.6 million 2023
Debt-to-Equity Ratio 0.32 2023
Interest Coverage Ratio 22.7x 2023



Is InMode Ltd. (INMD) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

InMode Ltd. financial valuation metrics reveal critical insights for potential investors:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio 16.5x
Price-to-Book (P/B) Ratio 4.2x
Enterprise Value/EBITDA 12.3x

Stock price performance analysis for the past 12 months:

  • 52-week low: $20.75
  • 52-week high: $72.60
  • Current stock price: $45.30
  • Price volatility: 38.5%

Analyst consensus breakdown:

Recommendation Percentage
Buy 65%
Hold 25%
Sell 10%

Additional financial indicators:

  • Dividend yield: 0%
  • Forward price/earnings ratio: 14.7x
  • Return on equity: 22.3%



Key Risks Facing InMode Ltd. (INMD)

Risk Factors for Medical Technology Company

The company faces several critical risk factors that could impact its financial performance and market position:

Market and Competitive Risks

Risk Category Potential Impact Probability
Market Competition Potential market share reduction High
Technological Disruption Potential obsolescence of current technologies Medium

Operational Risks

  • Supply chain disruptions potentially impacting 35% of production capacity
  • Regulatory compliance challenges in multiple international markets
  • Potential intellectual property disputes

Financial Risks

Key financial vulnerabilities include:

  • Revenue volatility of approximately 22% year-over-year
  • Potential currency exchange rate fluctuations affecting international revenues
  • Research and development investment risks

Regulatory Environment Risks

Regulatory Domain Potential Risk Level Estimated Impact
FDA Approval Processes High Complexity $3.5M-$5.2M potential compliance costs
International Medical Device Regulations Moderate Complexity $2.1M estimated annual compliance expenditure

Strategic Risks

  • Potential market expansion challenges
  • Technology integration complexities
  • Talent acquisition and retention risks



Future Growth Prospects for InMode Ltd. (INMD)

Growth Opportunities

The company's growth trajectory is supported by several key strategic initiatives and market dynamics:

  • Global Market Expansion: Targeting $1.5 billion aesthetic medical device market by 2026
  • Product Innovation Pipeline: Developing 3-4 new technological platforms annually
  • International Revenue Growth: Focusing on 30% international market penetration
Growth Metric 2023 Performance 2024 Projection
Revenue Growth $385.2 million $460-480 million
R&D Investment $42.3 million $55-60 million
New Market Entry 5 countries 8-10 countries

Key competitive advantages include:

  • Proprietary energy-based medical aesthetic technologies
  • Strong intellectual property portfolio with 52 active patents
  • Minimally invasive treatment solutions with proven clinical efficacy

Strategic partnership highlights:

  • Collaboration with 12 leading medical research institutions
  • Distribution agreements in 35 countries
  • Expanding physician training programs globally

DCF model

InMode Ltd. (INMD) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.